Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanot...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9660 4900
Fax: 61 3 9660 4909
Address:
535 Bourke Street, Level 22, Melbourne, Australia
